AR091185A1 - 1,2,4-TRIAZOL DERIVATIVES - Google Patents

1,2,4-TRIAZOL DERIVATIVES

Info

Publication number
AR091185A1
AR091185A1 ARP130101863A AR091185A1 AR 091185 A1 AR091185 A1 AR 091185A1 AR P130101863 A ARP130101863 A AR P130101863A AR 091185 A1 AR091185 A1 AR 091185A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
optionally substituted
heterocycloalkyl
haloalkyl
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Schaffhauser Herve
Groebke Zbinden Katrin
Kuhn Bernd
Lerner Christian
Flohr Alexander
Rudolph Markus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48534382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR091185A1 publication Critical patent/AR091185A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos. Reivindicación 1: Un compuesto de la fórmula (1) ó (2) en las que: B es alquileno C₁₋₄, alquenileno C₂₋₄, alquinileno C₂₋₄, cicloalquilo C₃₋₅; R¹ y R² se eligen con independencia entre hidrógeno, alquilo C₁₋₇ opcionalmente sustituido por cicloalquilo C₃₋₅; hidroxialquilo C₁₋₇, alcoxialquilo C₁₋₇, haloalquilo C₁₋₇, cicloalquilo C₃₋₅, R¹ y R² junto con el átomo de nitrógeno, al que están unidos, forman un azaespirocicloalquilo, un anillo bicíclico o un heterocicloalquilo que pueden estar sustituidos de 1 a 3 veces por sustituyentes elegidos con independencia entre el grupo formado por halógeno, alquilo C₁₋₇, alcoxialquilo C₁₋₇; hidroxi-alquilo C₁₋₇, alcoxi C₁₋₇, haloalquilo C₁₋₇, hidroxilo, -NR⁹R¹⁰ y oxo; R³ se elige entre hidrógeno, cicloalquilo C₃₋₅, alcoxialquilo C₁₋₇, haloalquilo C₁₋₇, heterocicloalquilo, -(CH₂)₀,₁,₂-arilo opcionalmente sustituido por alcoxi C₁₋₇ y alquilo C₁₋₇ opcionalmente sustituido por cicloalquilo C₃₋₅; R⁴ se elige entre heteroarilo opcionalmente sustituido de 1 a 3 veces por sustituyentes elegidos entre halógeno, alquilo C₁₋₇, hidroxialquilo C₁₋₇, haloalcoxi C₁₋₇, halo-alquilo C₁₋₇, cicloalquilo C₃₋₅, ciano, amino, nitro, -O-R⁶-C(O)-R⁷, -SO₂R⁸, alcoxi C₁₋₂ opcionalmente sustituido por alcoxi C₁₋₂, heterocicloalquilo; R⁶ y R⁸ se eligen entre alquilo C₁₋₇; R⁷ se elige entre heterocicloalquilo; R⁹ y R¹⁰ se eligen con independencia entre hidrógeno, alquilo C₁₋₇, -C(O)-O-alquilo C₁₋₇.These compounds inhibit PDE10A and can be used as medicines. Claim 1: A compound of the formula (1) or (2) wherein: B is C₁₋₄ alkylene, C₂₋₄ alkenylene, C₂₋₄ alkynylene, C₃₋₅ cycloalkyl; R¹ and R² are independently selected from hydrogen, C₁₋₇ alkyl optionally substituted by C₃₋₅ cycloalkyl; C₁₋₇ hydroxyalkyl, C₁₋₇ alkoxyalkyl, C₁₋₇ haloalkyl, C₃₋₅ cycloalkyl, R¹ and R² together with the nitrogen atom, to which they are attached, form an azaspirocycloalkyl, a bicyclic ring or a heterocycloalkyl which may be substituted by 1 to 3 times by substituents independently selected from the group consisting of halogen, C₁₋₇ alkyl, C₁₋₇ alkoxyalkyl; hydroxy-C₁₋₇ alkyl, C alco alkoxy, C₁₋₇ haloalkyl, hydroxyl, -NR⁹R¹⁰ and oxo; R³ is selected from hydrogen, C₃₋₅ cycloalkyl, C₁₋₇ alkoxyalkyl, C₁₋₇ haloalkyl, heterocycloalkyl, - (CH₂) ₀, ₁, ₂-aryl optionally substituted by C₁₋₇ alkoxy and C₁₋₇ alkyl optionally substituted by cycloalkyl C₃₋₅; R⁴ is selected from heteroaryl optionally substituted 1 to 3 times by substituents chosen from halogen, C₁₋₇ alkyl, C₁₋₇ hydroxyalkyl, C₁₋₇ haloalkoxy, C₁₋₇ haloalkyl, C₃₋₅ cycloalkyl, cyano, amino, nitro , -O-R⁶-C (O) -R⁷, -SO₂R⁸, C₁₋₂ alkoxy optionally substituted by C₁₋₂ alkoxy, heterocycloalkyl; R⁶ and R⁸ are chosen from C₁₋₇ alkyl; R⁷ is selected from heterocycloalkyl; R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₇ alkyl, -C (O) -O-C₁₋₇ alkyl.

ARP130101863 2012-05-30 2013-05-29 1,2,4-TRIAZOL DERIVATIVES AR091185A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12169954 2012-05-30

Publications (1)

Publication Number Publication Date
AR091185A1 true AR091185A1 (en) 2015-01-14

Family

ID=48534382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101863 AR091185A1 (en) 2012-05-30 2013-05-29 1,2,4-TRIAZOL DERIVATIVES

Country Status (21)

Country Link
US (1) US9394311B2 (en)
EP (1) EP2855455B1 (en)
JP (1) JP5992096B2 (en)
KR (1) KR101666293B1 (en)
CN (1) CN104364249B (en)
AR (1) AR091185A1 (en)
AU (1) AU2013269800A1 (en)
BR (1) BR112014026828A2 (en)
CA (1) CA2868240A1 (en)
CL (1) CL2014002847A1 (en)
CO (1) CO7091174A2 (en)
CR (1) CR20140481A (en)
EA (1) EA201492069A1 (en)
IL (1) IL235829A0 (en)
MX (1) MX2014014468A (en)
PE (1) PE20142366A1 (en)
PH (1) PH12014502294A1 (en)
SG (1) SG11201406890YA (en)
TW (1) TW201402564A (en)
WO (1) WO2013178572A1 (en)
ZA (1) ZA201407695B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2603931T3 (en) * 2012-11-07 2017-03-02 F. Hoffmann-La Roche Ag Triazolo compounds
US10723723B2 (en) 2016-11-03 2020-07-28 Bristol-Myers Squibb Company Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors
CN111875583B (en) * 2017-10-17 2021-06-15 中国科学院上海药物研究所 Triazole derivative and preparation method and application thereof
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MX2020012376A (en) 2018-05-18 2021-03-09 Incyte Corp Fused pyrimidine derivatives as a2a / a2b inhibitors.
AU2019297361A1 (en) 2018-07-05 2021-02-25 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
BR112020013697A2 (en) 2018-11-06 2020-12-01 H. Lundbeck A/S compounds to treat negative symptoms and cognitive impairments
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
US11746107B2 (en) * 2019-09-25 2023-09-05 Molecure S.A. Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine
CN113929634A (en) * 2021-11-22 2022-01-14 山西永津集团有限公司 Synthesis method of 2, 3-dibromoquinoxaline

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2744116A (en) * 1953-12-04 1956-05-01 Purdue Research Foundation Bis-(aminotriazolyl-)-hydrocarbons
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
JP2007508241A (en) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Method for treating diabetes and related disorders using PDE10A inhibitors
US20080234252A1 (en) * 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
JP2009504592A (en) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション Xanthine derivatives as selective HM74A agonists
WO2008103357A1 (en) * 2007-02-21 2008-08-28 E. I. Du Pont De Nemours And Company Fungicidal tricyclic 1,2,4-triazoles
CN101678014B (en) * 2007-05-21 2012-12-12 Sgx药品公司 Heterocyclic kinase modulators
TWI501965B (en) * 2008-06-20 2015-10-01 Lundbeck & Co As H Novel phenylimidazole derivatives as pde10a enzyme inhibitors
TWI487705B (en) * 2009-12-17 2015-06-11 Lundbeck & Co As H Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103052639B (en) * 2010-08-12 2016-02-17 贝林格尔.英格海姆国际有限公司 6-cycloalkyl-1,5-dihydro-pyrazol is [3,4-d] pyrimidin-4-one-derivatives and the purposes as PDE9A inhibitor thereof also
US20130225583A1 (en) * 2010-10-21 2013-08-29 Gerald W. Shipps, Jr. Substituted amino-triazolyl pde10 inhibitors

Also Published As

Publication number Publication date
CN104364249A (en) 2015-02-18
CR20140481A (en) 2014-11-17
CN104364249B (en) 2018-04-17
CL2014002847A1 (en) 2015-01-30
CA2868240A1 (en) 2013-12-05
JP5992096B2 (en) 2016-09-14
ZA201407695B (en) 2016-08-31
US9394311B2 (en) 2016-07-19
EP2855455A1 (en) 2015-04-08
PH12014502294A1 (en) 2014-12-15
AU2013269800A1 (en) 2014-10-09
SG11201406890YA (en) 2014-11-27
EP2855455B1 (en) 2017-11-08
KR101666293B1 (en) 2016-10-13
US20150148332A1 (en) 2015-05-28
PE20142366A1 (en) 2015-01-10
JP2015518018A (en) 2015-06-25
MX2014014468A (en) 2015-02-12
WO2013178572A1 (en) 2013-12-05
KR20150027143A (en) 2015-03-11
TW201402564A (en) 2014-01-16
CO7091174A2 (en) 2014-10-21
BR112014026828A2 (en) 2017-06-27
EA201492069A1 (en) 2015-03-31
IL235829A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
AR091185A1 (en) 1,2,4-TRIAZOL DERIVATIVES
AR088449A1 (en) BENZILINDAZOLES REPLACED
AR094557A1 (en) TIADIAZOL, ANALOGS OF THE SAME, AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO SMN DEFICIENCY
AR092108A1 (en) PIRIDAZINE 1.4 DISSTITUTED, ANALOGS OF THE SAME AND METHODS TO TREAT DISEASES RELATED TO SMN DEFICIENCY
AR090488A1 (en) DERIVATIVES OF N-CYCLLOBUTILBENZAMIDE, A PROCESS FOR OBTAINING, INTERMEDIARIES FOR SYNTHESIS, PESTICIDES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND METHODS FOR CONTROLLING DAMAGES DUE TO A PEST AND / OR FUNDS
AR106301A1 (en) PIRROLPIRIMIDINE COMPOSITIONS AS KINASE INHIBITORS
AR089699A1 (en) IMIDAZOLS AND REPLACED FUSIONED PIRAZOLS AND ITS
ES2620668T3 (en) Spirocyclic amido and sulfonamide derivatives
AR091279A1 (en) MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
AR088829A1 (en) CYCLHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS
AR092568A1 (en) TRICYCLE DERIVATIVES OF QUINOLINAS AND QUINOXALINAS
AR087711A1 (en) INHIBITORS OF QUINURENINA-3-MONOOXIGENASA, PHARMACEUTICAL COMPOSITIONS AND USE OF THEM FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
PE20130376A1 (en) [1,8] NAPHTHYRIDINES SUBSTITUTED BY 2,4-DIARYLL AS KINASE INHIBITORS FOR USE AGAINST CANCER
AR058010A1 (en) BICYCLE DERIVATIVES AS P38 INHIBITORS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
AR084553A1 (en) HIDEROCICLIC INHIBITING IMIDAZOLIC DERIVATIVES OF b-SECRETASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER
ES2603931T3 (en) Triazolo compounds
ES2626801T3 (en) Triazolopyridine compounds as pde10a inhibitors
AR095708A1 (en) INDAZOLS REPLACED WITH DIAMINOHETEROARILO
AR087771A1 (en) PDE10 MODULATORS
AR110498A1 (en) DERIVATIVES OF ISOXAZOLIL Ether AS POSITIVE ALOSTERIC MODULATORS (PAM) OF GABAA RECEPTORS a5
AR097755A1 (en) SUBSTITUTED DERIVATIVES OF PHENYLALANINE AS MODULATORS OF THE XIA FACTOR
AR103742A1 (en) DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA
AR093758A1 (en) ARIL LACTAMA QUINASA INHIBITORS
AR107321A1 (en) ANTIPROLIFERATIVE COMPOUNDS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES
AR097754A1 (en) SUBSTITUTED DERIVATIVES OF PHENYLALANINE

Legal Events

Date Code Title Description
FB Suspension of granting procedure